(P122) Older African Americans’ Use of Religious Music to Cope With Cancer

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Religion and particularly the use of religious songs are important aspects of coping with the cancer experience among older African Americans. During diagnosis and treatment, a religious song is likely to be a viable complement to therapies for symptom reduction and mood elevation among this population.

Jill B. Hamilton, PhD, Angelo D. Moore, PhD, FNP, Kayoll Galbraith, BSN, Peter A. Johnstone, MD; Johns Hopkins University School of Nursing; Center for Nursing Science and Clinical Inquiry, Womack Army Medical Center, US Army; University of North Carolina, Chapel Hill; Moffitt Cancer Center

OBJECTIVE: Among Americans, African Americans are more likely to pray at least daily, report affiliations with a religious group, indicate that religion is very important in their lives, and indicate that they are certain God exists. An extensive body of literature on African-American spirituals informs regarding the use of religious songs to manage life stressors, such as a cancer diagnosis.

METHODS: A total of 65 African-American men and women residing in the southeastern United States were interviewed. Inclusion criteria included: African-American ethnicity by self-report, age at least 50 years, and having experienced the loss of a loved one or a life-threatening illness. Semistructured interviews lasting 15–60 min were conducted between 2008 and 2010. These interviews were held in participants’ homes or private rooms located in their churches. Participants were given a $25 gift card for participating. All interviews were audiotaped and transcribed verbatim. Initial steps of content analysis were to construct a table that organized the data collected, including participants’ responses on whether a song, scripture, or prayer was used; the words of the songs, scriptures, and prayers; the personal meanings of the songs, scriptures, or prayers; and the outcomes derived from using any of these religious expressions. Five categories of religious songs derived from the data were: Thanksgiving and Praise, Instructive, Memory of Forefathers, Communication With God, and Belief in Life After Death.

RESULTS: Of the participants interviewed, 23 indicated that cancer was their most stressful life event. The most frequent type song used was Thanksgiving and Praise (n = 9, 39%), followed by Instructive (n = 8, 35%), Communication with God (n = 7, 30%), Belief in Life after Death (n = 5, 22%), and Memory of Forefathers (n = 3, 13%). The most frequently reported outcomes were comfort (n = 9, 39%), hope (n = 9, 39%), and strength (n = 9, 39%). The least frequently reported outcomes were peace of mind (n = 8, 35%), support (n = 6, 26%), protection (n = 1, 4%), and guidance (n = 1, 4%).

CONCLUSIONS: Religion and particularly the use of religious songs are important aspects of coping with the cancer experience among older African Americans. During diagnosis and treatment, a religious song is likely to be a viable complement to therapies for symptom reduction and mood elevation among this population.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
Related Content